Addison Capital Co Sells 432 Shares of Johnson & Johnson (NYSE:JNJ)

Addison Capital Co trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,965 shares of the company’s stock after selling 432 shares during the quarter. Johnson & Johnson makes up about 2.8% of Addison Capital Co’s investment portfolio, making the stock its 9th largest holding. Addison Capital Co’s holdings in Johnson & Johnson were worth $6,937,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Gold Investment Management Ltd. boosted its holdings in Johnson & Johnson by 1.0% in the fourth quarter. Gold Investment Management Ltd. now owns 17,389 shares of the company’s stock worth $2,515,000 after purchasing an additional 168 shares in the last quarter. Creative Financial Designs Inc. ADV lifted its position in shares of Johnson & Johnson by 7.6% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 9,509 shares of the company’s stock worth $1,375,000 after buying an additional 668 shares during the last quarter. IMG Wealth Management Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter worth about $483,000. Signature Wealth Management Group increased its holdings in shares of Johnson & Johnson by 4.9% during the 4th quarter. Signature Wealth Management Group now owns 27,864 shares of the company’s stock valued at $4,030,000 after acquiring an additional 1,295 shares during the last quarter. Finally, SlateStone Wealth LLC raised its stake in shares of Johnson & Johnson by 2.4% in the 4th quarter. SlateStone Wealth LLC now owns 69,864 shares of the company’s stock valued at $10,104,000 after acquiring an additional 1,637 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on JNJ. Morgan Stanley lowered their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Stifel Nicolaus cut their target price on shares of Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Down 0.0 %

Shares of JNJ opened at $162.94 on Monday. The stock has a 50 day simple moving average of $154.98 and a 200-day simple moving average of $156.27. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43. The stock has a market cap of $392.29 billion, a PE ratio of 24.50, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.29 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.04%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.